The institution is ad portas of the beginning of this study. Do you want to participate? The page is already enabled, as well as the corresponding registration platform in the link https://tetrafluvac.cl
UC Communications.- TetraFluVacCL is a Phase 3 Clinical Study being carried out in Chile to evaluate the safety of a tetravalent vaccine against influenza (flu), developed by the Laboratory SINOVAC, compared to another equivalent vaccine that already exists. “This and other studies that we are leading from the UC allow us to obtain very relevant information from the first source regarding the performance of vaccines in the Chilean population, while improving our understanding of how vaccines work,” says Dr. Alexis Kalergis, tenured professor at UC and director of the Millennium Institute for Immunology and Immunotherapy (IMII).
Dr. Pablo González, associate professor at the UC and also a researcher at the IMII, comments that “this scientific-clinical study is carried out in association with various hospital and clinical centers in the Metropolitan Region and regions, and is sponsored by the Pontificia Universidad Católica de Chile, which, through a team of academics from various faculties, coordinates the study that is expected to result in scientific publications.
“The study is aimed at volunteers from 3 years of age, with no maximum age limit, and will analyze the neutralizing capacity of antibodies in the blood against influenza viruses and will compare it with that generated by another vaccine with similar characteristics”- Dr. Susan Bueno, UC Scholar Share
«The study is aimed at volunteers from the age of 3, with no maximum age limit. “The study will analyze the neutralizing capacity of antibodies in the blood against influenza viruses and will compare it with that generated by another vaccine with similar characteristics,” he comments. Dr. Susan Bueno, tenured professor at UC, and IMII researcher.
Visit the registration page www.tetrafluvac.cl for more information.
You can also enroll to participate in a study of variant vaccines SARS-CoV-2, and in the scientific-clinical study CoronaVarCL, evaluating a new booster dose against the Omicron variant of SAR-CoV-2.
